Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

NCT01563536 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG: ABT-267
DRUG: ABT-450
DRUG: ABT-333
DRUG: Ritonavir
DRUG: Ribavirin

Sponsor

AbbVie (prior sponsor, Abbott)